Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZOSTAVAX one-dose vs two-dose regimens in adults ≥70 years
2007-000744-28Phase 3Completed
- Sponsor
- Sanofi Pasteur MSD S.N.C.
- Start
- Jul 2007
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoster vaccine, live in herpes zoster (HZ) and postherpetic neuralgia (PHN) (3 arms), sponsored by Sanofi Pasteur MSD S.N.C. Primary endpoints: Primary immunogenicity endpoint, VZV antibody titre summaries and 1 more. Started Jul 2007; status: completed.
02
Drugs
zoster vaccine, live
03
Conditions
herpes zoster (HZ)postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on 2007-000744-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000744-28.